- Home
- Publications
- Publication Search
- Publication Details
Title
Checkpoint inhibitors in AML: are we there yet?
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 188, Issue 1, Pages 159-167
Publisher
Wiley
Online
2019-12-07
DOI
10.1111/bjh.16358
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
- (2019) Anas Younes et al. Lancet Haematology
- Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT
- (2019) Maddalena Noviello et al. Nature Communications
- Immune checkpoint blockade toxicity among patients with cancer presenting to the emergency department
- (2019) Olivier Peyrony et al. EMERGENCY MEDICINE JOURNAL
- Immunotherapy of melanoma: facts and hopes
- (2019) Sarah A Weiss et al. CLINICAL CANCER RESEARCH
- Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab
- (2019) V. Quagliariello et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
- (2019) Radhakrishnan Ramchandren et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
- (2019) Robert Chen et al. BLOOD
- Hepatotoxicity of immune check point inhibitors: Approach and management
- (2019) Ana Lleo et al. DIGESTIVE AND LIVER DISEASE
- Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
- (2019) Farhad Ravandi et al. Lancet Haematology
- ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)
- (2018) G. Redelman-Sidi et al. CLINICAL MICROBIOLOGY AND INFECTION
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells
- (2018) Yixiang Han et al. Frontiers in Immunology
- Expanding Therapeutic Opportunities for Hematopoietic Stem Cell Transplantation: T Cell Depletion as a Model for the Targeted Allograft
- (2018) Christina Cho et al. Annual Review of Medicine
- Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC
- (2018) Florent Malard et al. Journal of Hematology & Oncology
- Immune Escape of Relapsed AML Cells after Allogeneic Transplantation
- (2018) Matthew J. Christopher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis
- (2018) Steven M. Bair et al. ONCOLOGIST
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study
- (2018) Naval Daver et al. Cancer Discovery
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- (2017) Jarushka Naidoo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Checkpoint Inhibition in Hodgkin Lymphoma - a Review
- (2017) Paul J. Bröckelmann et al. Oncology Research and Treatment
- Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies
- (2016) Miguel-Angel Perales et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant
- (2016) Ibraheem H. Motabi et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma
- (2016) Maria Del Castillo et al. CLINICAL INFECTIOUS DISEASES
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Ipilimumab for Patients with Relapse after Allogeneic Transplantation
- (2016) Matthew S. Davids et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
- (2016) Claire F. Friedman et al. JAMA Oncology
- Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation
- (2015) Miguel-Angel Perales et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- 5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft
- (2015) J Steinmann et al. BONE MARROW TRANSPLANTATION
- Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis
- (2015) Omar Abdel-Rahman et al. Future Oncology
- Novel immunotherapies in lymphoid malignancies
- (2015) Connie Lee Batlevi et al. Nature Reviews Clinical Oncology
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT
- (2014) B Tessoulin et al. BONE MARROW TRANSPLANTATION
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
- (2014) B. Liao et al. NEURO-ONCOLOGY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab in patients with melanoma and autoimmune disease
- (2014) Chrisann Kyi et al. Journal for ImmunoTherapy of Cancer
- Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Introduction
- (2013) Alan S. Wayne et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
- (2013) B. J. Chen et al. CLINICAL CANCER RESEARCH
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
- (2013) T Schroeder et al. LEUKEMIA
- Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells
- (2013) Y Wei et al. LEUKEMIA
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- T Cell–Depleted Unrelated Donor Stem Cell Transplantation Provides Favorable Disease-Free Survival for Adults with Hematologic Malignancies
- (2011) Ann A. Jakubowski et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
- (2010) Ted A. Gooley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relapse after Allogeneic Hematopoietic Cell Therapy
- (2009) Marcel R.M. van den Brink et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
- (2009) S. M. Ansell et al. CLINICAL CANCER RESEARCH
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
- (2008) A. Bashey et al. BLOOD
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now